Status:

COMPLETED

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Schizophrenia Disorders

Eligibility:

All Genders

18-55 years

Phase:

PHASE2

Brief Summary

This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.

Eligibility Criteria

Inclusion

  • Diagnosis of schizophrenia
  • Symptomatically stable and currently treated with a stable regimen for at least 3 (three) months prior to dosing with one of the following second generation of antipsychotics: risperidone, paliperidone, quetiapine, ziprasidone, aripiprazole.
  • Specific cognitive impairment
  • Smokers and non-smokers

Exclusion

  • Current treatment with an anticholinergic or other agent known to adversely interfere with the cholinergic system, and/ or treatment with cholinesterase inhibitor within the last three (3) months prior to dosing.
  • Current treatment with conventional antipsychotics (e.g fluphenazine, haloperidol) or clozapine.
  • History of neuroleptic malignant syndrome.
  • Diagnosis of substance abuse (other than nicotine) within the last month and alcohol or substance dependence (other than nicotine) within the last 6 months.
  • Any clinically significant suicidal ideation (Type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last month) or previous history of suicide behavior Other protocol-defined inclusion/exclusion criteria may apply

Key Trial Info

Start Date :

May 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2011

Estimated Enrollment :

57 Patients enrolled

Trial Details

Trial ID

NCT01163227

Start Date

May 1 2010

End Date

September 1 2011

Last Update

December 24 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,

Glendale, California, United States, 91206

2

CRI Worldwide, 1113 Hospital Dr. Suite 202,

Willingboro, New Jersey, United States, 08046